Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1995 Mar;39(3):243–249. doi: 10.1111/j.1365-2125.1995.tb04443.x

Evaluation of the alpha 2-adrenoceptor blocking properties of buspirone and ipsapirone in healthy subjects. Relationship with the plasma concentration of the common metabolite 1-(2-pyrimidinyl)-piperazine.

I Berlin 1, S Chalon 1, C Payan 1, G Schöllnhammer 1, F Cesselin 1, O Varoquaux 1, A J Puech 1
PMCID: PMC1364998  PMID: 7619663

Abstract

1. Because the 5-HT1A agonist anxiolytic azapirones have a common alpha 2-adrenoceptor antagonist metabolite, 1-(2-pyrimidinyl)-piperazine (1PP), we measured central and peripheral alpha 2-adrenoceptor dependent responses before and after intravenous administration of 0.15 mg clonidine when healthy subjects were taking buspirone (30 mg day-1 for 4 days and 10 mg on day 5), ipsapirone (15 mg day-1 for 4 days and 5 mg on day 5) or placebo. 2. Clonidine decreased blood pressure, heart rate, oral body temperature, salivary excretion, plasma noradrenaline, 3,4-dihydroxyphenylglycol (DHPG) concentrations, increased plasma growth hormone but did not modify plasma insulin and C-peptide concentrations. Treatments tended to modify only the effect of clonidine on growth hormone (P = 0.07). 3. The azapirones reduced clonidine induced prolongation of choice reaction time (P = 0.015) and tended to antagonise clonidine induced fall in critical flicker fusion frequency (P = 0.066). 4. Only buspirone reduced total reaction time and increased critical flicker fusion threshold measured 12 h after the evening dose and these effects were correlated with the residual plasma 1PP concentration which was higher on buspirone than on ipsapirone (2.76 micrograms l-1, 95% CI:1.3-4.22 vs 0.65 microgram l-1, 95% CI: 0.32-0.98, P = 0.006). 5. Mean AUC of the 1PP plasma concentrations after the last dose of treatments were 3.7 times greater with buspirone than with ipsapirone (P = 0.0011). The AUC ipsapirone/AUC 1PP ratio was 6.45 and the AUC buspirone/AUC 1PP ratio was 0.076.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
243

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson I. M., Cowen P. J. Effect of pindolol on endocrine and temperature responses to buspirone in healthy volunteers. Psychopharmacology (Berl) 1992;106(3):428–432. doi: 10.1007/BF02245430. [DOI] [PubMed] [Google Scholar]
  2. Bianchi G., Caccia S., Della Vedova F., Garattini S. The alpha 2-adrenoceptor antagonist activity of ipsapirone and gepirone is mediated by their common metabolite 1-(2-pyrimidinyl)-piperazine (PmP). Eur J Pharmacol. 1988 Jul 14;151(3):365–371. doi: 10.1016/0014-2999(88)90532-8. [DOI] [PubMed] [Google Scholar]
  3. Bianchi G., Caccia S. Simultaneous determination of buspirone, gepirone, ipsapirone and their common metabolite 1-(2-pyrimidinyl)piperazine in rat plasma and brain by high-performance liquid chromatography. J Chromatogr. 1988 Oct 14;431(2):477–480. doi: 10.1016/s0378-4347(00)83123-0. [DOI] [PubMed] [Google Scholar]
  4. Bianchi G., Garattini S. Blockade of alpha 2-adrenoceptors by 1-(2-pyrimidinyl)-piperazine (PmP) in vivo and its relation to the activity of buspirone. Eur J Pharmacol. 1988 Mar 15;147(3):343–350. doi: 10.1016/0014-2999(88)90167-7. [DOI] [PubMed] [Google Scholar]
  5. Blier P., Curet O., Chaput Y., de Montigny C. Tandospirone and its metabolite, 1-(2-pyrimidinyl)-piperazine--II. Effects of acute administration of 1-PP and long-term administration of tandospirone on noradrenergic neurotransmission. Neuropharmacology. 1991 Jul;30(7):691–701. doi: 10.1016/0028-3908(91)90176-c. [DOI] [PubMed] [Google Scholar]
  6. Borison R. L., Albrecht J. W., Diamond B. I. Efficacy and safety of a putative anxiolytic agent: ipsapirone. Psychopharmacol Bull. 1990;26(2):207–210. [PubMed] [Google Scholar]
  7. Caccia S., Conti I., Viganò G., Garattini S. 1-(2-Pyrimidinyl)-piperazine as active metabolite of buspirone in man and rat. Pharmacology. 1986;33(1):46–51. doi: 10.1159/000138199. [DOI] [PubMed] [Google Scholar]
  8. Cervo L., Grignaschi G., Samanin R. Different effects of intracerebral and systemic administration of buspirone in the forced swimming test: involvement of a metabolite. Life Sci. 1988;43(25):2095–2102. doi: 10.1016/0024-3205(88)90359-1. [DOI] [PubMed] [Google Scholar]
  9. Chaouloff F., Baudrie V., Laude D. Evidence that the 5-HT1A receptor agonists buspirone and ipsapirone activate adrenaline release in the conscious rat. Eur J Pharmacol. 1990 Feb 20;177(1-2):107–110. doi: 10.1016/0014-2999(90)90558-n. [DOI] [PubMed] [Google Scholar]
  10. Charney D. S., Heninger G. R. Abnormal regulation of noradrenergic function in panic disorders. Effects of clonidine in healthy subjects and patients with agoraphobia and panic disorder. Arch Gen Psychiatry. 1986 Nov;43(11):1042–1054. doi: 10.1001/archpsyc.1986.01800110028005. [DOI] [PubMed] [Google Scholar]
  11. Charney D. S., Heninger G. R., Breier A. Noradrenergic function in panic anxiety. Effects of yohimbine in healthy subjects and patients with agoraphobia and panic disorder. Arch Gen Psychiatry. 1984 Aug;41(8):751–763. doi: 10.1001/archpsyc.1984.01790190025003. [DOI] [PubMed] [Google Scholar]
  12. Charney D. S., Heninger G. R., Sternberg D. E. Assessment of alpha 2 adrenergic autoreceptor function in humans: effects of oral yohimbine. Life Sci. 1982 Jun 7;30(23):2033–2041. doi: 10.1016/0024-3205(82)90444-1. [DOI] [PubMed] [Google Scholar]
  13. Chignon J. M., Lepine J. P. Panic and hypertension associated with single dose of buspirone. Lancet. 1989 Jul 1;2(8653):46–47. doi: 10.1016/s0140-6736(89)90287-0. [DOI] [PubMed] [Google Scholar]
  14. Cowen P. J., Anderson I. M., Grahame-Smith D. G. Neuroendocrine effects of azapirones. J Clin Psychopharmacol. 1990 Jun;10(3 Suppl):21S–25S. doi: 10.1097/00004714-199006001-00005. [DOI] [PubMed] [Google Scholar]
  15. Cutler N. R., Sramek J. J., Keppel Hesselink J. M., Krol A., Roeschen J., Rickels K., Schweizer E. A double-blind, placebo-controlled study comparing the efficacy and safety of ipsapirone versus lorazepam in patients with generalized anxiety disorder: a prospective multicenter trial. J Clin Psychopharmacol. 1993 Dec;13(6):429–437. [PubMed] [Google Scholar]
  16. Dompert W. U., Glaser T., Traber J. 3H-TVX Q 7821: identification of 5-HT1 binding sites as target for a novel putative anxiolytic. Naunyn Schmiedebergs Arch Pharmacol. 1985 Feb;328(4):467–470. doi: 10.1007/BF00692918. [DOI] [PubMed] [Google Scholar]
  17. Funck-Brentano C. Topics in clinical pharmacology: buspirone: a new nonbenzodiazepine anxiolytic agent. Am J Med Sci. 1989 Jan;297(1):49–52. doi: 10.1097/00000441-198901000-00012. [DOI] [PubMed] [Google Scholar]
  18. Gammans R. E., Mayol R. F., LaBudde J. A. Metabolism and disposition of buspirone. Am J Med. 1986 Mar 31;80(3B):41–51. doi: 10.1016/0002-9343(86)90331-1. [DOI] [PubMed] [Google Scholar]
  19. Giral P., Martin P., Soubrié P., Simon P. Reversal of helpless behavior in rats by putative 5-HT1A agonists. Biol Psychiatry. 1988 Feb 1;23(3):237–242. doi: 10.1016/0006-3223(88)90034-0. [DOI] [PubMed] [Google Scholar]
  20. Giral P., Soubrie P., Puech A. J. Pharmacological evidence for the involvement of 1-(2-pyridinyl)-piperazine (1-PmP) in the interaction of buspirone or gepirone with noradrenergic systems. Eur J Pharmacol. 1987 Jan 28;134(1):113–116. doi: 10.1016/0014-2999(87)90139-7. [DOI] [PubMed] [Google Scholar]
  21. Goa K. L., Ward A. Buspirone. A preliminary review of its pharmacological properties and therapeutic efficacy as an anxiolytic. Drugs. 1986 Aug;32(2):114–129. doi: 10.2165/00003495-198632020-00002. [DOI] [PubMed] [Google Scholar]
  22. Halliday R., Callaway E., Lannon R. The effects of clonidine and yohimbine on human information processing. Psychopharmacology (Berl) 1989;99(4):563–566. doi: 10.1007/BF00589909. [DOI] [PubMed] [Google Scholar]
  23. Lesch K. P., Rupprecht R., Poten B., Müller U., Söhnle K., Fritze J., Schulte H. M. Endocrine responses to 5-hydroxytryptamine-1A receptor activation by ipsapirone in humans. Biol Psychiatry. 1989 Jun;26(2):203–205. doi: 10.1016/0006-3223(89)90024-3. [DOI] [PubMed] [Google Scholar]
  24. Lesch K. P., Söhnle K., Poten B., Schoellnhammer G., Rupprecht R., Schulte H. M. Corticotropin and cortisol secretion after central 5-hydroxytryptamine-1A (5-HT1A) receptor activation: effects of 5-HT receptor and beta-adrenoceptor antagonists. J Clin Endocrinol Metab. 1990 Mar;70(3):670–674. doi: 10.1210/jcem-70-3-670. [DOI] [PubMed] [Google Scholar]
  25. Martin P. 1-(2-pyrimidinyl)-piperazine may alter the effects of the 5-HT1A agonist in the learned helplessness paradigm in rats. Psychopharmacology (Berl) 1991;104(2):275–278. doi: 10.1007/BF02244191. [DOI] [PubMed] [Google Scholar]
  26. Meltzer H. Y., Flemming R., Robertson A. The effect of buspirone on prolactin and growth hormone secretion in man. Arch Gen Psychiatry. 1983 Oct;40(10):1099–1102. doi: 10.1001/archpsyc.1983.01790090061009. [DOI] [PubMed] [Google Scholar]
  27. Nocon H., Daniel W., Danek L., Melzacka M. Cerebral pharmacokinetics of ipsapirone in rats after different routes of administration. J Pharm Pharmacol. 1990 Sep;42(9):642–645. doi: 10.1111/j.2042-7158.1990.tb06623.x. [DOI] [PubMed] [Google Scholar]
  28. Rickels K. Buspirone in clinical practice. J Clin Psychiatry. 1990 Sep;51 (Suppl):51–54. [PubMed] [Google Scholar]
  29. Schmidt B. H., Chaouloff F. Chronic treatment with an anxiolytic dose of the 5-HT1A agonist ipsapirone does not alter ipsapirone acute neuroendocrine effects. Psychoneuroendocrinology. 1993;18(7):457–466. doi: 10.1016/0306-4530(93)90039-n. [DOI] [PubMed] [Google Scholar]
  30. Söderpalm B., Hjorth S., Engel J. A. Effects of 5-HT1A receptor agonists and L-5-HTP in Montgomery's conflict test. Pharmacol Biochem Behav. 1989 Jan;32(1):259–265. doi: 10.1016/0091-3057(89)90242-6. [DOI] [PubMed] [Google Scholar]
  31. Warren J. B., Dollery C. T., Fuller R. W., Williams V. C., Gertz B. J. Assessment of MK-912, an alpha 2-adrenoceptor antagonist, with use of intravenous clonidine. Clin Pharmacol Ther. 1989 Jul;46(1):103–109. doi: 10.1038/clpt.1989.113. [DOI] [PubMed] [Google Scholar]
  32. Warren J. B., Dollery C. T., Sciberras D., Goldberg M. R. Assessment of MK-467, a peripheral alpha 2-adrenergic receptor antagonist, with intravenous clonidine. Clin Pharmacol Ther. 1991 Jul;50(1):71–77. doi: 10.1038/clpt.1991.105. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES